title: Feasibility of proton beam therapy for chordoma and chondrosarcoma of the skull base.
abstract: We explored the general feasibility of proton beam therapy for chordoma and chondrosarcoma of the skull base. Clinical records and treatment-planning data of patients with the pathological diagnosis of chordoma or chondrosarcoma were examined. Proton beam therapy was administered for gross tumor mass as well as microscopic residual disease after surgery. The prescribed dose was determined to maximize the coverage of the target and to not exceed predefined constraints for the organs at risk. Eight cases of chordoma and eight cases of chondrosarcoma were enrolled. The median tumor volume was 40 cm(3) (range, 7 to 546 cm(3)). The prescribed dose ranged from 50 to 70 Gy (relative biological effectiveness [RBE]), with a median of 63 Gy RBE. The median follow-up duration was 42 months (range 9 to 80 months). The overall survival rate was 100%, and the local control rate at 3 years of chordoma and chondrosarcoma were 100% and 86%. None of the patients developed radiation-induced optic neuropathy, brain stem injury, or other severe toxicity. Proton beam therapy is generally feasible for both chordoma and chondrosarcoma of the skull base, with excellent local control and survival rates.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Fuji
authors.forename: Yoko
authors.initials: Y
authors.lastname: Nakasu
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ishida
authors.forename: Satoshi
authors.initials: S
authors.lastname: Horiguchi
authors.forename: Koichi
authors.initials: K
authors.lastname: Mitsuya
authors.forename: Hiroya
authors.initials: H
authors.lastname: Kashiwagi
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Murayama